Arcus Biosciences (RCUS) Equity Income (2018 - 2020)

Arcus Biosciences' Equity Income history runs 3 years deep, the most recent figure standing at -$131000.0 for Q2 2020.

• In Q2 2020, Equity Income rose 68.2% year-over-year to -$131000.0; the TTM figure through Mar 2021 stood at -$131000.0 (up 89.53% YoY), while the FY2020 annual figure was -$613000.0, up 49.0% from the prior year.
• Equity Income was -$131000.0 for Q2 2020 at Arcus Biosciences, up from -$482000.0 in the prior quarter.
• In the past five years, Equity Income ranged from a high of -$131000.0 in Q2 2020 to a low of -$482000.0 in Q1 2020.
• Historically, Equity Income has averaged -$299888.9 across 3 years, with a median of -$323000.0 in 2018.
• The sharpest annual moves came in 2019 and 2020: Equity Income slumped 172.85% in 2019, then jumped 68.2% in 2020.
• A 3-year view of Equity Income shows it stood at -$323000.0 in 2018, then dropped by 10.53% to -$357000.0 in 2019, then soared by 63.31% to -$131000.0 in 2020.
• The last three Equity Income figures came in at -$131000.0 (Q2 2020), -$482000.0 (Q1 2020), and -$357000.0 (Q3 2019), per Business Quant data.